Table 3 Univariate analyses of response to therapy, time to progression and overall survival
Response rate | P | TTP | P | OS | P | |
|---|---|---|---|---|---|---|
Hb levels⩾12 g dl−1 | 40.4% (151/374) | 11.7 | 26.4 | |||
Hb levels<12 g dl−1 | 29.2% (75/257) | 0.004 | 10.0 | <0.001 | 20.2 | <0.0001 |
5FU DI ⩾1165 mg sqm week−1 | 43.1% (110/255) | 11.6 | 24.9 | |||
5FU DI<1165 mg sqm week−1 | 34.0%(86/253) | <0.0001 | 10.5 | 0.07 | 25.2 | NS |
Therapy with oxaliplatin | 45.8% (163/356) | 11.6 | 25.1 | |||
Therapy without oxaliplatin | 22.9% (63/275) | <0.0001 | 9.8 | 0.004 | 22.3 | <0.001 |
Therapy with irinotecan | 28% (14/50) | 9.5 | 25.3 | |||
Therapy without irinotecan | 36.5% (212/581) | NS | 10.9 | NS | 23.3 | NS |
Infusional regimen | 37.1% (141/380) | 11.8 | 23.9 | |||
Bolus+infusional regimen | 33.5% (84/251) | NS | 10.0 | 0.004 | 23.3 | NS |
PS 0 | 46.1% (154/334) | 11.9 | 29.0 | |||
PS 1 | 28.8% (45/156) | 9.9 | 20.1 | |||
PS 2 | 26.7% (8/30) | <0.001 | 7.6 | <0.001 | 11.0 | <0.0001 |
Liver mts | 38.7% (177/457) | 10.8 | 23.3 | |||
No liver mts | 28.2% (49/174) | 0.01 | 10.9 | NS | 24.7 | NS |
Lung mts | 40.0% (66/165) | 13.1 | 30.0 | |||
No lung mts | 34.3% (160/466) | NS | 10.4 | <0.001 | 22.2 | <0.001 |
Male | 36.1% (139/385) | 11.0 | 24.3 | |||
Female | 35.4% (87/246) | NS | 10.6 | NS | 23.2 | NS |
